Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Evolus Inc (GB:0K16)
LSE:0K16
Holding GB:0K16?
Track your performance easily
0K16 Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$7.50 - $17.67
Previous Close$16
Volume138.00
Average Volume (3M)870.00
Market Cap
$1.04B
Enterprise Value$1.07B
Total Cash (Recent Filing)$93.67M
Total Debt (Recent Filing)$126.75M
Price to Earnings (P/E)―
Beta0.18
Next Earnings
Nov 05, 2024EPS Estimate
-$0.12Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding63,094,482
10 Day Avg. Volume646
30 Day Avg. Volume870
Standard Deviation0.22
R-Squared0.00569
Alpha0.02
Financial Highlights & Ratios
Price to Book (P/B)51.42
Price to Sales (P/S)4.35
Price to Cash Flow (P/CF)-39.80
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue4.52
Enterprise Value/Gross Profit7.64
Enterprise Value/Ebitda-49.17
Forecast
1Y Price Target
$23.80Price Target Upside48.71% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
Evolus News
PremiumCompany Announcements
Evolus Announces Board Appointments and Committee ChangesBulls Say, Bears Say
Bulls Say
Market ExpansionThe new filler opportunity significantly expands the company’s Total Addressable Market (TAM).
Product PerformanceEvolus reported positive data for dermal filler products, with no treatment-related serious adverse events and a safety profile consistent across both products.
Sales GrowthJeuveau sales growth appears to be gaining momentum with increasing brand recognition and penetration of new accounts.
Bears Say
EarningsThe higher spending led to a wider non-GAAP EPS loss of -$0.21 compared to consensus estimates.
Market CompetitionKey risks include inability to capture market share due to competitive response.
Supply ChainKey risks include disruption to supply chain.
---
Options Prices
Currently, No data available
---
Ownership Overview
8.76% Insiders
9.50% Mutual Funds
48.27% Other Institutional Investors
22.56% Public Companies and
Individual Investors
0K16 FAQ
What was Evolus Inc’s price range in the past 12 months?
Evolus Inc lowest share price was $7.50 and its highest was $17.67 in the past 12 months.
What is Evolus Inc’s market cap?
Currently, no data Available
When is Evolus Inc’s upcoming earnings report date?
Evolus Inc’s upcoming earnings report date is Nov 05, 2024 which is in 28 days.
How were Evolus Inc’s earnings last quarter?
Evolus Inc released its earnings results on Jul 31, 2024. The company reported -$0.039 earnings per share for the quarter, beating the consensus estimate of -$0.052 by $0.013.
Is Evolus Inc overvalued?
According to Wall Street analysts Evolus Inc’s price is currently Undervalued.
Does Evolus Inc pay dividends?
Evolus Inc does not currently pay dividends.
What is Evolus Inc’s EPS estimate?
Evolus Inc’s EPS estimate is -$0.12.
How many shares outstanding does Evolus Inc have?
Evolus Inc has 63,094,482 shares outstanding.
What happened to Evolus Inc’s price movement after its last earnings report?
Evolus Inc reported an EPS of -$0.039 in its last earnings report, beating expectations of -$0.052. Following the earnings report the stock price went up 7.072%.
Which hedge fund is a major shareholder of Evolus Inc?
Among the largest hedge funds holding Evolus Inc’s share is Perceptive Advisors LLC. It holds Evolus Inc’s shares valued at 62M.
---
Evolus Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$23.80 (48.71% Upside)
$23.80 (48.71% Upside)
Blogger Sentiment
Bullish
GB:0K16 Sentiment 75%
Sector Average 70%
Sector Average 70%
Insider Transactions
Sold Shares
Worth $138.3K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Positive
20 days / 200 days
Momentum
86.96%
12-Months-Change
Fundamentals
Return on Equity
-861.68%
Trailing 12-Months
Asset Growth
38.34%
Trailing 12-Months
Company Description
Evolus Inc
Evolus, Inc. is a medical aesthetics company, which engages in the provision of medical aesthetic treatments and procedures. It offers products under the brand of Jeuveau. The company was founded by Scott Cannizzaro in November, 2012 and is headquartered in Newport Beach, CA.
---
0K16 Company Deck
---
0K16 Earnings Call
Q2 2024
0:00 / 0:00
---
0K16 Stock 12 Month Forecast
Average Price Target
$23.80
▲(48.71% Upside)
Technical Analysis
Best Analysts Covering 0K16
1 Year
1 Year Success Rate
15/19 ratings generated profit
1 Year Average Return
+23.07%
reiterated a buy rating 6 days ago
Copying Douglas Tsao's trades and holding each position for 1 Year would result in 78.95% of your transactions generating a profit, with an average return of +23.07% per trade.
---